PROGRAM MENU

EDUCATIONAL PROGRAM

PRE-SUMMIT WORKSHOPS

SATELLITE SYMPOSIA


Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2024 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.


  Wed - Apr 03      Thu - Apr 04      Fri - Apr 05      Sat - Apr 06   

FRIDAY, APRIL 5

6:30 - 8:00 PM
EVENT/OTHER
REGISTRATION
Chicago Promenade

7:00 - 8:00 AM
SATELLITE SYMPOSIUM
ADVANCES IN ITTP MANAGEMENT CONTEMPORARY CLINICAL APPROACHES (SPONSORED BY SANOFI)
Chicago Ballroom VI

Please join our Sanofi Medical Affairs Rare Blood Disorders team for our medical symposium to gain expert insights on prioritizing clinical management of aTTP/iTTP, focusing on early treatment, and achieving durable responses from therapies, ultimately resulting in improved clinical outcomes. The symposium will be presented in two parts and will illustratively describe the iTTP pathophysiology, epidemiology/diagnostic considerations, before discussing the ISTH guidelines on diagnosis and treatment of iTTP and important implications on clinical management of iTTP.



HEMOSTASIS 2. 0: RETHINKING HEMOPHILIA MANAGEMENT AND MONITORING WITH ANTI-TFPIS AND FVIII MIMETICS (IN PARTNERSHIP WITH CME OUTFITTERS, LLC. SUPPORTED BY AN EDUCATIONAL GRANT FROM NOVO NORDISK, INC. )
Chicago Ballroom IX-X

In this CME Outfitters live activity, experts in hemophilia, including a patient who has lived with the disorder for many years, discuss the role of these newer therapies, how they work, and how to implement them in practice to improve quality of care and outcomes. A focused exercise in shared decision making keeps the conversation grounded in counseling and care and includes both clinician and patient perspectives. This activity is certified for 1. 0 hours of ACCME, ANCC, AAPA, and ABIM MOC II credit.


8:15 - 9:45 AM
LABORATORY
EVOLUTION OF THE CLINICAL HEMOSTASIS/THROMBOSIS LABORATORY
Chicago Ballroom VII


8:15

EVOLUTION OF HEMOSTASIS/THROMBOSIS LABORATORY PHYSICIAN ROLE--CLINICAL CONSULTANT
Evelyn Cortina.


8:45

EVOLUTION OF HEMOSTASIS/THROMBOSIS LABORATORY PROFESSIONAL ROLE AT THE BENCH
Jing Jin.


9:15

EVOLUTION OF HEMOSTASIS/THROMBOSIS LABORATORY METHODS INCLUDING LABORATORY AUTOMATION (ELISA-->LIA, MANUAL-->AUTOMATED ADAMTS13, ON-DEMAND VS. BATCH TESTING, NEW VON WILLEBRAND ASSAYS)
Rusty Higgins.

8:15 - 9:45 AM
THROMBOSIS / BASIC SCIENCE
FXI & FXII
Sheraton Ballroom IV-V


8:15

CONTACT INHIBITON IN ECMO
Joe Palumbo.


8:45

ROLE OF ANTIPLATELET AND ANTICOAGULANT THERAPY IN VENO-OCCLUSIVE CRISIS (VOC)
Erica Sparkenbaugh.


9:15

STATE OF THE ART ON FXI AND FXII INHIBITOR DATA
Jeff Weitz.

8:15 - 9:45 AM
HEMOSTASIS
NOT YOUR MOM'S JEANS: UPDATES ON GENE THERAPY FOR HEMOPHILIA PATIENTS
Sheraton Ballroom I-II


8:15

CONSIDERING GENE THERAPY IN THE CONTEXT OF NEW OPTIONS FOR MANAGEMENT OF HEMOPHILIA
Ben Samelson-Jones.


8:45

LIVER DISEASE IN THE ERA OF GENE THERAPY
Ype P De Jong.


9:15

MANAGING MEDICAL CHALLENGES OF GENE THERAPY
Stacy Croteau.

9:45 - 10:30 AM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Riverwalk AB


A1. ANTICOAGULATION CLINICS




ANALYSIS OF PHARMACIST INTERVENTIONS WITHIN A DIRECT ORAL ANTICOAGULATION MANAGEMENT PROTOCOL
Clara J Nickel2, Anne E Rose1. 1University of Wisconsin Health, Madison, WI, USA. 2University of Wisconsin School of Pharmacy, Madison, WI, USA


A3. VASCULAR WALL BIOLOGY, ENDOTHELIAL PROGENITOR CELLS AND PLATELET ADHESION




CHARACTERIZATION OF THE ENDOTHELIAL CELL SUBPOPULATIONS MARKED BY TEK AND CDH5 PROMOTER DRIVEN CRE EXPRESSION IN DIFFERENT MOUSE STRAINS
David Svilar1, 2, Audrey Cleuren1, 3, David Siemieniak1, David Ginsburg1, 2, 4, 5. 1Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA. 2Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA. 3Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA. 4Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 5Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION




ELECTRONIC MEDICAL RECORD INTERVENTIONS IN REDUCING INAPPROPRIATE TESTING FOR HEPARIN INDUCED THROMBOCYTOPENIA: EXPERIENCE IN A LARGE TEACHING HOSPITAL SYSTEM
Mukul Singal1, 2, Soon K. Low3, 4, Peter A. Kouides5, 6, Maura Wychowski6, Ronald L. Sham5, 6. 1Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA. 2Hematology and Oncology Fellowship, Rochester General Hospital, Rochester, NY, USA. 3Internal Medicine Residency Program, Rochester General Hospital, Rochester, NY, USA. 4Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. 5Mary M. Gooley Hemophilia and Thrombosis Center, Rochester, NY, USA. 6Department of Hematology and Oncology, Rochester General Hospital, Rochester, NY, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS




ARTIFICIAL INTELLIGENCE AND VENOUS THROMBOEMBOLISM: TALKING TO THE EXPERTS
Anuranita Gupta1, Barbara D Lam2, 13, Sabrina Zerbey2, William Robertson3, Rachel P Rosovsky4, Leslie Lake5, Laura Dodge6, Alys Adamski7, Nimia Reyes7, Karon Abe7, Ioannis Vlachos8, Jeffrey I Zwicker9, 10, Mara Schonberg11, Rushad Patell12. 1Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA. 2Division of Hematology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA. 3Weber State University, Ogden, UT. 4Division of Hematology a Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA. 5National Blood Clot Alliance, Philadelphia, PA. 6Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA. 7Division of Blood Disorders and Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GA. 8Department of Pathology, Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, MA. 9Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NYC, NY. 10Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NYC, NY. 11Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, MA. 12Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. 13Division of Clinical Informatics, Beth Israel Deaconess Medical Center, Boston, MA




CIRCULATING NUCLEIC ACID, ERNA IS A NOVEL ACTIVATOR OF TISSUE FACTOR AND COAGULATION IN HYPOXIA
Gausal Khan1, Saumya Bhagat2. 1King Faisal University, Al Ahsa, Saudi Arabia. 2Washington University School of Medicine, St. Louis, MO, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS




T-HLPER CYTOKINE INTERACTIONS WITH BAFF IN THE FACTOR VIII IMMUNE RESPONSE
Tammi L. Briscoe1, Mostafa A. Shaheen1, Bhavya S. Doshi1, 2. 1Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA




SURGICAL AND PROCEDURAL OUTCOMES FOR PATIENTS WITH FACTOR VIII DEFICIENCY TAKING EMICIZUMAB PROPHYLACTICALLY: A REGIONAL APPROACH TO DATA COLLECTION AND ANALYSIS
Janice Kuhn1, Butler Regina2, Mailie-Howell Lisa2, Druzgal Colleen3, Sennett Margy3. 1Virginia Commonwealth University, Richmond, VA, USA. 2Children's Hospital of Philadelphia, Philadelphila, PA, USA. 3University of Virginia, Charlottesville, VA, USA




TRENDS OF ACUTE ISCHEMIC STROKE IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: A DECADE STUDY
Ayobami Olafimihan1, Stanley ozogbo2, Praise fawehinmi3, Gbolahan Olatunji4, Emmanuel Kokori4, Aderinto Nicholas5, Ekrem Turk1, Lina George1, Shaka Hafeez1. 1John H. Stroger Jr Hospital, Chicago, IL, USA. 2Mercy Health- St. Elizabeth Hospital, Youngstown, OH, USA. 3Southern Illinois University Edwardsville, Chicago, IL, USA. 4University of Ilorin, Ilorin, Nigeria. 5Ladoke Akintola University of Technology, Ogbomosho, Nigeria




SUSTAINED EFFICACY AND SAFETY 3 YEARS FOLLOWING INFUSION WITH ETRANACOGENE DEZAPARVOVEC IN ADULTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA B IN THE PHASE 3 HOPE-B CLINICAL TRIAL
Steven W. Pipe1, Paul van der Valk2, Peter Verhamme3, Peter Kampmann4, Frank Leebeek5, Michiel Coppens6, Nigel Key7, Nathan Visweshwar8, Guy Young9, Richard Lemons10, Robert Klamroth11, Niamh O'Connell12, Sandra le Quellec13, Paul Monahan13, Cedric Hermans14. 1Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA. 2Van Creveldkliniek, University Medical Center Utrecht, Utrecht, Netherlands. 3Center for Molecular and Vascular Biology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium. 4Rigshospitalet, Copenhagen, Denmark. 5Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands. 6Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands. 7University of North Carolina, Chapel Hill, NC, USA. 8University of South Florida, Tampa, FL, USA. 9University of Southern California Keck School of Medicine, Childrena, Los Angeles, CA, USA. 10University of Utah, Salt Lake City, UT, USA. 11Vivantes Klinikum im Friedrichshain, Berlin, Germany. 12National Coagulation Centre, St. Jamesa, Dublin, Ireland. 13CSL Behring, King of Prussia, PA, USA. 14Division of Haematology, Cliniques Universitaires Saint-Luc, UniversitAc Catholique de Louvain (UCLouvain), Brussels, Belgium




LONG-TERM SAFETY AND EFFICACY OF FITUSIRAN PROPHYLAXIS IN A PHASE 1/2 OPEN-LABEL EXTENSION STUDY IN PEOPLE WITH MODERATE OR SEVERE HEMOPHILIA A OR B
Steven W. Pipe1, Toshko Lissitchkov2, Sarah Mangles3, Pencho Georgiev4, Erin Feng5, Laurel A. Menapace6, Salim Kichou7, Shauna Andersson6, Marek Demissie6, Margaret Ragni8. 1University of Michigan, Ann Arbor, MI, USA. 2Clinic Specialized Hospital for Active Treatment of Haematological Diseases, Sofia, Bulgaria. 3Haemophilia, Haemostasis and Thrombosis Centre, Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom. 4University Multiprofile Hospital for Active Treatment, Plovdiv, Bulgaria. 5Sanofi, Shanghai, China. 6Sanofi, Cambridge, MA, USA. 7Sanofi, Paris, France. 8University of Pittsburgh and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA




FOURTH INTERIM ANALYSIS OF THE HEM-POWR STUDY: EVALUATING REAL-WORLD EFFECTIVENESS AND SAFETY OF DAMOCTOCOG ALFA PEGOL IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA A IN THE UNITED STATES
Mark T Reding1, Beng Fuh2, Vanessa Salinas3, Maissaa Janbain4. 1University of Minnesota Medical Center, Minneapolis, MN, USA. 2East Carolina University, Greenville, NC, USA. 3Center for Inherited Blood Disorders, Orange, CA, USA. 4Tulane School of Medicine, New Orleans, LA, USA




EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A: SUMMARY OF 10 YEARS OF SAFETY DATA ON THROMBOEMBOLIC EVENTS AND THROMBOTIC MICROANGIOPATHY
Katayon Sarouei1, Simona Barlera2, Letizia Polito3, Guillermo Tobaruela3, Juliana M. L Biondo1. 1Genentech, Inc, South San Francisco, CA, USA. 2Parexel International, Milan, Italy. 3F. Hoffmann-La Roche Ltd, Basel, Switzerland




ACQUIRED VON WILLEBRAND SYNDROME IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: A FOCUS ON RESPONSE TO TREATMENT WITH IVIG
Tanna Tan1, Rajiv K. K. Pruthi2, Aneel A. Ashrani2, Meera Sridharan2. 1Division of Internal Medicine, Mayo Clinic, Rochester, MN, USA. 2Division of Hematology/Oncology, Mayo Clinic, Rochester, MN, USA




TITLE: RECOMBINANT ADAMTS13 REPLACEMENT THERAPY IN A PEDIATRIC PATIENT WITH CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA.
Katrina` Unpingco1, Michael F. Guerrera2, Zahara Jones1, Alison Matsunaga1. 1Hemophilia and Thrombosis Center UCSF Benioff Children's Hospitals, Oakland -San Francisco, CA, USA. 2Hemostasis and Thrombosis Center, Children's National Medical Center, Washington, DC, USA


A8. ANTITHROMBOTIC THERAPY




THE ANTICOAGULATED TRAUMA PATIENT IN THE WILDERNESS
Emma DeLoughery, Thomas DeLoughery. Oregon Health a Science University, Portland, OR, USA




TIME TO STABLE THERAPEUTIC ANTICOAGULATION USING WEIGHT-BASED IV HEPARIN DOSING CLINICAL DECISIONS SUPPORT PROGRAM
Keri S. Kim, Jean Lee, Miranda Hart, John Garofalo, Jeffrey J. Mucksavage. University of Illinois Chicago College of Pharmacy, Chicago, IL, USA




MONITORING BIVALIRUDIN ANTICOAGULANT EFFECT BY THE ADDITION OF DILUTED THROMBIN TIME COMPARED TO ACTIVATED PARTIAL THROMBOPLASTIN TIME ALONE
Vadim Kostousov, Karen Bruzdoski, Jun Teruya. Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA




COMPARATIVE PROTAMINE SULFATE AND HEPA-REMOVE NEUTRALIZATION STUDIES IN POTENCY ADJUSTED PORCINE AND BOVINE HEPARIN
Emily Krupa, Debra Hoppensteadt-Moorman, Walter Jeske, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)




THE RISK OF RECURRENT VENOUS THROMBOEMBOLSIM AND HEMORRHAGE IN THE POSTPARTUM PATIENT REQURING ANTICOAGULATION
Thomas Kiebalo1, 2, Ann Malinowski1, 4, Jose Carvalho1, 5, Nadine Shehata1, 2, 3. 1Mount Sinai Hospital, Toronto, ON, Canada. 2Department of Medicine, University of Toronto, Toronto, ON, Canada. 3Department of Hematology, University of Toronto, Toronto, ON, Canada. 4Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada. 5Department of Anesthesiology, University of Toronto, Toronto, ON, Canada




NOVEL THROMBOPHILIA- PROTHROMBIN BELGRADE VARIANT IN A MEXICAN FAMILY
Natalie/A Montanez1, 3, Miguel/A Escobar1, 2, 3. 1University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Houston, TX, USA. 2University of Texas Health Science Center of Houston, McGovern Medical School, Department of Internal Medicine, Houston, TX, USA. 3Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA

10:30 - 11:30 AM
SHORT TALKS
SHORT TALKS - BLEEDING BACK TO THE BASICS
Sheraton Ballroom I-II


10:30

GERMINAL CENTER AND NON-GERMINAL CENTER B CELL RESPONSE TO FACTOR VIII IN HEMOPHILIA A PATIENTS
Maya Maarouf1, Ian Smith1, Wallace H Baldwin1, John F Healey1, Ernest T Parker1, Courtney Cox1, Robert F Sidonio, Jr1, Karen L Zimowski1, Glaivy Batsuli2, Bhavya S Doshi3, Shannon L Meeks1, Seema R Patel1. 1Aflac Cancer and Blood Disorders Center, Childrena, Atlanta, GA, USA. 2Stanford University, Palo Alto, CA, USA. 3Department of Pediatrics, Division of Hematology, Childrena, Philadelphia, PA, USA


10:45

ENHANCED ACTIVATION OF FVIII POSITIVELY IMPACTS CLOT FORMATION IN VIVO USING HEMOPHILIA A MICE
Lacramioara Ivanciu1, 2, Mettine H. A. Bos1, Rodney M. Camire1, 2. 1The Children's Hospital of Philadelphia, Division of Hematology and the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Philadelphia, PA, USA. 2University of Pennsylvania, Department of Pediatrics, Philadelphia, PA, USA


11:00

INTRINSIC XASE LIGAND INTERACTIONS IMPACT FVIIIA REGULATION
John J Morris1, 2, Nicole A Parsons2, Robert J Davidson1, Lindsey A George1, 2. 1Children's Hospital of Philadelphia, Philadelphia, PA, USA. 2University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA


11:15

PROCOAGULANT RESCUE OF HEMOPHILIA B CAUSING FACTOR IX VARIANTS BY FACTOR FVIII MIMETICS
Kyumin Lee1, 2, Yani Suber1, 2, Julia Q. Chau1, 2, Sebastian E. Leyes Porello1, 2, Bhavya S. Doshi1, 2, Ben J. Samelson-Jones1, 2. 1The Childrena, Philadelphia, PA, USA. 2University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA


SHORT TALKS - INDUSTRY THROMBOSIS - NO CME
Chicago Ballroom VII


10:30

EFFICACY AND SAFETY IS MAINTAINED IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RECEIVING PEGCETACOPLAN FOR UP TO 3 YEARS
Carlos de Castro1, Brian Mulherin2, 3, Christopher J. Patriquin4, Veena Selvaratnam5, Raymond Siu Ming Wong6, Richard J. Kelly7, Lisa Tan8, 9, Peter Hillmen10, Dale Zhang10, Regis Peffault de Latour11, 12. 1Duke University, Durham, NC, USA. 2Hematology Oncology of Indiana, Indianapolis, IN, USA. 3Ascension St. Vincent Carmel, Carmel, IN, USA. 4University Health Network, Toronto, ON, Canada. 5Ampang Hospital, Ampang, Malaysia. 6The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong. 7Department of Haematology, St. Jamesa, Leeds, United Kingdom. 8Swedish Orphan Biovitrum AB, Stockholm, Sweden. 9Lisa Tan Pharma Consulting Ltd, Cambridge, United Kingdom. 10Apellis Pharmaceuticals, Inc, Waltham, MA, USA. 11French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Paris, France. 12UniversitAc Paris CitAc, Paris, France


10:45

SAFETY AND EFFICACY OF LONG-TERM TREATMENT OF TYPE 1 PLASMINOGEN DEFICIENCY PATIENTS WITH INTRAVENOUS PLASMINOGEN REPLACEMENT THERAPY
Amy D Shapiro1, Heather McDaniel2, Robert W Decker3, Jeremy Lorber3, Karen Thibaudeau4, Joseph M Parker5. 1Indiana Hemophilia a Thrombosis Center, Indianapolis, IN, USA. 2Vanderbilt University, Nashville, TN, USA. 3Cedars Sinai Medical Center, Los Angeles, CA, USA. 4Kedrion, Laval, Canada. 5Kedrion, Fort Lee, NJ, USA


11:00

TOLERABILITY AND PHARMACODYNAMIC EFFECT OF REGN9933, A MONOCLONAL ANTIBODY DIRECTED AGAINST THE FACTOR XI APPLE 2 DOMAIN: RESULTS FROM A FIRST-IN-HUMAN STUDY
Ethan Marin1, Guixian Lin1, Hisham Abdallah1, David Gutstein1, Andrew Kordahi2, Karoline Meagher1, Frederic Cauwberghs3. 1Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA. 2Regeneron Pharmaceuticals, Inc. (at time of study), Tarrytown, NY, USA. 3SGS (at time of study), Antwerp, Belgium


SHORT TALKS - TAKING LAB MONITORING TO THE NEXT LEVEL
Sheraton Ballroom IV-V


10:30

FACTOR II AND X (FIIX) MONITORED WARFARIN IS MORE EFFECTIVE THAN PT-INR MONITORED WARFARIN AND DIRECT ORAL ANTICOAGULANTS IN PATIENTS ANTICOAGULATED LONG-TERM FOR NON-VALVULAR ATRIAL FIBRILLATION. THE GREATER REYKJAVIK ORAL ANTICOAGULATION (GROAC) STUDY.
Arnar B. Ingason1, 2, Brynja R. Gudmundsdottir1, Ragnar Palsson1, 3, 4, Arnar S. Agustsson1, Edward Rumba1, Daniel A. Palsson1, Indridi Reynisson1, Sigrun H. Lund5, Johann P. Hreinsson6, Einar S. Bjornsson1, 5, Pall T. Onundarson1, 5. 1Landspitali National University Hospital, Reykjavik, Iceland. 2University of Vermont, Burlington, VT, USA. 3Massachusetts General Hospital, Boston, MA, USA. 4Harvard University, Boston, MA, USA. 5University of Iceland, Reykjavik, Iceland. 6Sahlgrenska University, Gothenburg, Sweden


10:45

DROP-OF-BLOOD COAGULATION ANALYSIS BY I-QATTTM
Huy Q Pham1, Collette Barnor1, Daishen Luo1, Elizabeth M Cummins1, Nithya Kasireddy1, Daniel Arango2, Shaun Yockelson3, Damir B Khismatullin1. 1Department of Biomedical Engineering, Tulane University, New Orleans, LA, USA. 2The University of Texas Medical Branch, Galveston, TX, USA. 3Department of Anesthesiology and Perioperative Medicine, Ochsner Medical Center, New Orleans, LA, USA


11:00

REAL-WORLD USE AND CORRELATION BETWEEN PLATELET-DEPENDANT ACTIVITY ASSAYS OF VON WILLEBRAND FACTOR (VWF):AB AND VWF:GP1BM IN PATIENTS WITH VON WILLEBRAND DISEASE IN THE AGE OF THE NEW GUIDELINES: A SINGLE-CENTER STUDY
Prarthana Parthasarathy, Kerry M Hege. Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, IN, USA


11:15

ICOAGLAB PERMITS COMPREHENSIVE COAGULATION PROFILING IN PATIENTS ON PERCUTANEOUS CARDIAC PUMP SUPPORT
Eli J Foster, Nathaniel Hai, Ziqian Zeng, Seemantini K Nadkarni. Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

11:45 - 12:45 PM
SATELLITE SYMPOSIUM
THE ROLE OF THE LIVER IN HEMOPHILIA GENE THERAPY & CLINICAL IMPLICATIONS (SPONSORED BY PFIZER)
Chicago Ballroom VI

The advent of liver directed-gene therapies in hemophilia has placed increasing interest on liver health in the pre and post infusion settings. This session will explore the role of the liver in hemophilia gene therapy including evaluation of liver heath and key considerations for clinical management from a hepatologists perspective.



VONVENDI PROPHYLAXIS FOR SEVERE TYPE 3 VON WILLEBRAND DISEASE PATIENT CASE DISCUSSION (SPONSORED BY TAKEDA PHARMACEUTICALS)
Chicago Ballroom IX-X

Join our expert HCP and a patient living with von Willebrand Disease (VWD) for an interactive journey. Our panel will guide you through the patients experience with VWD, review their treatment history, and discuss how VONVENDI may be added to the treatment plan for prophylaxis.


12:45 - 1:30 PM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Riverwalk AB


A2. PLATELET ACTIVATION AND BIOCHEMISTRY




LYN TRANSMITS PLATELET ACTIVATION SIGNALS BY DIRECTLY BINDING TO THE TRANSMEMBRANE/CYTOPLASMIC DOMAIN INTERFACE OF GPIBβ
Yaping Zhang1, Ying Liang1, Amir Hossein Kazemipour Ashkezari2, Can Wang1, Claire Chang1, Yanyan Bai1, Ni Cheng1, Peiwen Cong3, Cheng Zhu2, 3, Xiaoping Du1. 1Department of Pharmacology and Regenerative Medicine, University of Illinois at Chicago, Chicago, IL, USA. 2George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, USA. 3Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION




EVALUATION OF ANTICOAGULATION MANAGEMENT IN PATIENTS WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA AWAITING DIAGNOSIS CONFIRMATION
Alyssa R. George, Katelyn Sylvester, Dareen Kanaan, Delaney Corcoran, Kenneth Lupi, Brian Schuler, Jean M. Connors. Brigham and Women's Hospital, Boston, MA, USA




NATURAL HISTORY OF BLEEDING, TRANSFUSION, AND ANTIBODY PREVALENCE IN A SUBSET OF HERMANSKY-PUDLAK SYNDROME PATIENTS: EFFECTS OF FREEZE-DRIED LYOPHILIZED PLATELET DERIVED HEMOSTAT EX VIVO
Keith Moskowitz, Michael Fitzpatrick, Lisa Booth, Maria Abreau-Blanco, Matthew Dickerson, Anna Yu, Anya Derbij, W. Allan Alexander. Cellphire Therapeutics, Inc, Rockville, MD, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS




CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL TREATMENT IN VERY HIGH TITER INHIBITOR MURINE MODEL REQUIRES CD19 AND BCMA TARGETING
Julia Q. Chau2, Caroline Markmann1, Zheng Zhang1, Michael C. Milone1, Bhavya S. Doshi2, 3, Vijay G. Bhoj1, Benjamin J. Samelson-Jones2, 3. 1Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 2The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. 3Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA




NORMALIZATION OF THROMBIN GENERATION RESULTS USING WITHIN-RUN PLASMA NORMALIZATOR SIMULTANEOUSLY.
Loic J. Letertre1, 2, Pall T. Onundarson1, Jon T. Bergthorsson1, 2. 1Landspitali - The National University Hospital, Reykjavik, Iceland. 2The University of Iceland, Reykjavik, Iceland


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS




CHILD HEMO-TEM OBSERVER-REPORTED OUTCOME MEASURE: UNDERSTANDING AND ASSESSING TREATMENT BURDEN IN CHILDREN WITH HEMOPHILIA
Meryl Brod1, Donald M. Bushnell2, Jesper Skov Neergaard3, Anne Kirstine Busk3, Vlady Ostrow4. 1The Brod Group, Mill Valley, CA, USA. 2Evidera|PPD, Bethesda, MD, USA. 3Novo Nordisk A/S, SAcborg, Denmark. 4Novo Nordisk Inc, Plainsboro, NJ, USA




LONG-TERM EVALUATION OF LIVER HEALTH IN PARTICIPANTS WHO RECEIVED FIDANACOGENE ELAPARVOVEC: DATA FROM A PHASE 1/2A STUDY WITH UP TO 6 YEARS OF FOLLOW UP
Jonathan Ducore1, Lindsey A George2, Ben J Samelson-Jones2, John Rasko3, Catherine McGuinn4, Adam Giermasz1, Jerome Teitel5, Katherine High6, Jeremy Rupon7, Annie Fang7, Lynne Smith7, Priya Patel7, Amit Chhabra7, Frank Plonski7, Matko Kalac7. 1UC David Comprehensive Cancer Center, Sacramento, CA, USA. 2Childrena, Philadelphia, PA, USA. 3Centenary Institute, Sydney, Australia. 4Weill Cornell Medical Center, New York, NY, USA. 5University of Toronto, Toronto, ON, Canada. 6University of Pennsylvania, Philadelphia, PA, USA. 7Pfizer Inc, New York, NY, USA




EMICIZUMAB FOR SEVERE VON WILLEBRAND DISEASE (VWD) AND VWD/HEMOPHILIA A: THE EMIVWD STUDY
Jonathan Roberts1, 2, MIchael Tarantino1, 2. 1Bleeding a Clotting Disorders Institute, Peoria, IL, USA. 2Departments of Pediatrics and Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA




DESIGN OF A PROSPECTIVE, OBSERVATIONAL, MULTICENTER STUDY OF THE EFFECTIVENESS OF EFANESOCTOCOG ALFA ON LONG-TERM JOINT HEALTH IN PATIENTS WITH HEMOPHILIA A IN THE UNITED STATES AND JAPAN
Jonathan C. Roberts1, Spencer Sullivan2, Eric F. Grabowski3, Doris Quon4, Jennifer Dumont5, Annemieke Willemze6, Nicole Tsao5. 1Bleeding a Clotting Disorders Institute, Peoria, IL, USA. 2Mississippi Center for Advanced Medicine, Madison, MS, USA. 3Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 4Orthopedic Hemophilia Treatment Center, Los Angeles, CA, USA. 5Sanofi, Cambridge, MA, USA. 6Sanofi, Amsterdam, Netherlands




SEROPREVALENCE AND SEROCONVERSION AMONG PEOPLE WITH HEMOPHILIA A IN THE UNITED STATES: OBSERVATIONS FROM THE SAAVY (SEROPREVALENCE OF AAV ANTIBODY) STUDY
Amy Shapiro1, Leonard A. Valentino2, 3, David Hinds4, Manil Vaghela5, Erin Goodman4, Karim Iskander4, George Dela Cerda 4, Kim Schafer6, Steven Pipe7. 1Indiana Hemophilia Thrombosis Center, Indianapolis, IN, USA. 2National Bleeding Disorders Foundation, New York, NY, USA. 3Rush University, Chicago, IL, USA. 4BioMarin Pharmaceutical, Novato, CA, USA. 5BioMarin Pharmaceutical, London, United Kingdom. 6Hemostasis and Thrombosis Center, UC Davis Health, Sacramento, CA, USA. 7Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA




REAL-WORLD DATA ON EMICIZUMAB PROPHYLAXIS IN OLDER PERSONS WITH HEMOPHILIA A: A RETROSPECTIVE SINGLE CENTER COHORT STUDY
Shalini Vemuru1, Stacey Fedewa2, 3, Christine Kempton2, 3 . 1Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA, USA. 2Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA. 3Hemophilia of Georgia Center for Bleeding a Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA, USA




CLINICAL UTILITY AND PERFORMANCE OF VON WILLEBRAND FACTOR ACTIVITY ASSAYS IN A NATIONAL REFERENCE LABORATORY: THE VITALANT COAGULATION LABORATORY'S EXPERIENCE WITH THE RISTOCETIN COFACTOR AND VWF:GP1BM ASSAYS
Angela Verdoni1, Mason Marshall2, Irina Chibisov1. 1Vitalant Coagulation Laboratory, Pittsburgh, PA, USA. 2Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA




BRAIN VOLUMES AND NEUROCOGNITIVE OUTCOMES IN CHILDREN WITH HEMOPHILIA A
Silvia Verhofste1, Ahmad Al-Huniti1, 2, Marci Novak1, Amy L. Conrad1, 5, 6, Ellen van der Plas3, 4, Lyndsay Harshman1, 5, 6, Janice M. Staber1, 5, 6. 1Stead Family Department of Pediatrics, University of Iowa, Iowa City, IA, USA. 2*Current Location - Mayo Clinic, Rochester, MN, USA. 3Department of Psychiatry, University of Iowa, Iowa City, IA, USA. 4*Current Location -University of Arkansas for Medical Sciences, Pediatrics Arkansas Children's Hospital, Hematology/Oncology, Little Rock, AR, USA. 5The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, IA, USA. 6Iowa Neuroscience Institute, Iowa City, IA, USA


A7. PATHOPHYSIOLOGY OF THROMBOSIS




UTILIZING ARTIFICIAL INTELLIGENCE TO RECONCILE INDETERMINATE LUPUS ANTICOAGULANT PANEL RESULTS
Hailey Gosnell, Diana Arroyo Lugo, Morayma Reyes Gil. Robert J. Tomsich Pathology and Laboratory Medicine Institute at Cleveland Clinic Foundation, Cleveland, OH, USA


A8. ANTITHROMBOTIC THERAPY




SINGLE CENTER RETROSPECTIVE COMPARISON OF BIVALIRUDIN AND HEPARIN FOR THERAPEUTIC ANTICOAGULATION IN PEDIATRIC PATIENTS
Clayton Habiger, Shannon Carpenter. Children's Mercy Hospital, Kansas City, MO, USA




TRANSITIONING FROM ORAL FACTOR XA INHIBITOR TO UNFRACTIONATED HEPARIN USING HEPARIN-CALIBRATED ANTI-XA LEVELS
Mahnoor M Khan1, Magdalena E Jasinska2, Jeremy P Kosacz3, Erin N Robinson1, Lisa M Thompson3, Brandon Pierce3, Anne E Rose1. 1UW Health - Madison, Madison, WI, USA. 2University of Wisconsin School of Pharmacy, Madison, WI, USA. 3UW Health - Northern Illinois, Rockford, IL, USA




COVID-19 VENOUS THROMBOEMBOLISM PROPHYLAXIS GUIDELINES
Sara McElroy1, 2, Emily Cramer1, 2, Lauren Amos1, 2. 1Children's Mercy Kansas City, Kansas City, MO, USA. 2University of Missouri-Kansas City, Kansas City, MO, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)




BENEFIT OF ALBUMIN INFUSION IN AN ELDERLY CIRRHOTIC PATIENT ON DOAC: ABOUT A CASE .
LAMIA AIT OUALI1, FARID SLIMANI2, SAMIA OULARBI1, SAMIR TINE1, 3. 1APHP RenAc Muret, Sevran, France. 2APHP Jean Verdier, Bondy, France. 3APHP Avicenne, Bobigny, France




THE SEVERE VON WILLEBRAND DISEASE PATIENT REGISTRY: A LONGITUDINAL NATURAL HISTORY AND PATIENT OUTCOMES STUDY
Johnna Cesta1, Mrinal Gounder1, Christopher Walsh 2, Alice Araphsian1, Jeanette Cesta1, Christina Morgenthaler1. 1VWD Connect Foundation, Wellington, FL, USA. 2Icahn School of Medicine Mount Sinai Hospital, New York, NY, USA

1:30 - 2:45 PM
PLENARY SESSION
ABORTION/REPRODUCTIVE HEALTH - WHEN THE LAW AND HEALTHCARE COLLIDE - HOW LAWS THAT RESTRICT ACCESS TO REPRODUCTIVE CARE ARE AFFECTING HEMOSTASIS AND THROMBOSIS PATIENTS
Sheraton Ballroom IV-V


1:30

EFFECT ON STEM CELL RESEARCH
Paul Blumenthal .


1:55

EFFECT ON PIPELINE - PERSONNEL, FUNDING
Alyssa Colwill.


2:20

IMPACT ON CLINICAL CARE THROMBOSIS AND HEMOSTASIS
Jeff Federspiel.

3:00 - 4:30 PM
THROMBOSIS
CLINICAL CHALLENGES FOR ANTITHROMBOTIC MANAGEMENT IN THE AMBULATORY CARE SETTING
Sheraton Ballroom IV-V


3:00

DE-ESCALATING ANTITHROMBOTIC THERAPY: HOW DO WE ENSURE APPROPRIATE USE
Cynthia Fenton.


3:30

PERIOPERATIVE CONSIDERATIONS FOR ANTICOAGULATION WITH MECHANICAL DEVICES AND HEART VALVES
James Douketis.


4:00

KEEPING ANTICOAGULATION CLINICS RELEVANT IN THE NEXT DECADE
Kelly Rudd.

3:00 - 4:30 PM
LABORATORY / BASIC SCIENCE
IMMUNOTHROMBOTIC SYNDROMES
Chicago Ballroom VII


3:00

MACHINE LEARNING FOR HIT
Adam Cuker.


3:30

IMMUNOTHROMBOSIS AND SEPTICEMIA
Alison Fox-Robichaud.


4:00

COMPLEMENT ACTIVATION BY HIT IMMUNE COMPLEXES
Sanjay Khandelwal.

3:00 - 4:30 PM
HEMOSTASIS
OUCH! PAIN AND BLEEDING DISORDERS
Sheraton Ballroom I-II


3:00

BIOPSYCHOSOCIAL PAIN MECHANISMS
Kalpna Gupta.


3:30

INTERDISCIPLINARY PAIN ASSESSMENT
Tyler Buckner.


4:00

BARRIERS AND SUCCESSES TO IMPLEMENTING INTERDISCIPLINARY MULTIMODAL PAIN MANAGEMENT
Lena Volland.

4:30 - 5:15 PM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Riverwalk AB


A2. PLATELET ACTIVATION AND BIOCHEMISTRY




IL-6-INDUCED POTENTIATION OF PLATELET ACTIVITY AND GLYCOSYLATION IN VENOUS THROMBOEMBOLISM
Michelle K. Brenner1, Karin Hoffmeister2, Brian Branchford1. 1Pediatric Hematology/Oncology/Bone Marrow Transplant, Childrena, Milwaukee, WI, USA. 2Translational Glycomics Center, Versiti Blood Research Institute, Milwaukee, WI, USA


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION




ATHN TRANSCENDS: NATURAL HISTORY COHORT STUDY OF BLEEDING SYMPTOMS AND TREATMENT OUTCOMES IN PATIENTS WITH GLANZMANN THROMBASTHENIA
Divyaswathi Citla Sridhar1, Sanjay Ahuja2, Tammuella Chrisentery-Singleton3, Carrie O'Neil3, Catherine Rea4, Jigar Amin4, Mike Recht5, 6, Meera Chitlur7. 1Arkansas Childrena, Little Rock, AR, USA. 2Rainbow Babies a Childrena, Cleveland, OH, USA. 3American Thrombosis and Hemostasis Network, Rochester, NY, USA. 4Hemab Therapeutics, Cambridge, MA, USA. 5National Bleeding Disorders Foundation, New York, NY, USA. 6Yale University School of Medicine, New Haven, CT, USA. 7Central Michigan University/Childrena, Detroit, MI, USA




UTILITY OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING (TEG-PM) FOR MONITORING PLATELET TRANSFUSION IN QUALITATIVE PLATELET DISORDERS
Robert H. Lee1, 2, Tanvi Rudran2, Wolfgang Bergmeier1, 2. 1Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 2UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS




TITLE: REAL-WORLD EFFICACY DATA ON ADOLESCENT HEMOPHILIA A PATIENTS TRANSITIONING TO BAY 81-8973 OR BAY 94-9027 IN THE ATHNDATASET
Michael Recht1, Jessica Charlet2, Thomas Moulton2, Michael Recht3, 4. 1American Thrombosis a Hemostasis, NetworkRochester, NY, USA. 2Bayer Pharmaceuticals, USA, Whippany, NJ, USA. 3National Bleeding Disorders Foundation, New York City, NY, USA. 4Yale University School of Medicine, New Haven, CT, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS




BURDEN OF DISEASE AND IMPACT ON QUALITY OF LIFE IN HEREDITARY FACTOR X DEFICIENCY PATIENTS WHO WERE DIAGNOSED AT BIRTH: FINDINGS FROM THE HEREDITARY FACTOR X DEFICIENCY IN AMERICA SURVEY
Kim Clark1, Amy Wu2, Denise A. Garner2, Lorie Mody2, Jaymin Patel2, Brian Branchford3. 1Kedrion Biopharma, INC, Fort Lee, NJ, USA. 2AESARA, INC, Chapel Hill, NC, USA. 3Versiti Blood Research Institute, Medical College of Wisconsin, and Children's Wisconsin, Milwaukee, WI, USA




REBLEED INCIDENCE WITH EPTACOG BETA TREATMENT THROUGH 24 AND 48 HOURS IN CHILDREN (UNDER 12 YEARS) WITH HEMOPHILIA A OR B WITH INHIBITORS
Amy L. Dunn1, Manuel Carcao2, Meera Chitlur3, Joanna Davis4, Nina Hwang5, Craig Kessler6, Catherine McGuinn7, Danielle Nance8, Robert Sidonio Jr. 9, Tammuella Chrisentery-Singleton10, Courtney D. Thornburg11, 12, Michael Wang13, Steven Pipe14. 1Nationwide Childrena, Columbus, OH, USA. 2The Hospital for Sick Children, Toronto, ON, Canada. 3Central Michigan University College of Medicine/Childrena, Detroit, MI, USA. 4Pediatric Hemophilia Treatment Center, University of Miami, Miami, FL, USA. 5Center for Inherited Blood Disorders, Orange, CA, USA. 6Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. 7Department of Pediatrics, Division of Pediatric Hematology/Oncology, Weill Cornell Medicine, New York, NY, USA. 8Banner MD Anderson Cancer Center, Gilbert, AZ, USA. 9Aflac Cancer and Blood Disorders Center and Emory University, Atlanta, GA, USA. 10American Thrombosis and Hemostasis Network, Rochester, NY, USA. 11Hemophilia and Thrombosis Treatment Center, Rady Children's Hospital-San Diego, San Diego, CA, USA. 12Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, USA. 13Hemophilia and Thrombosis Center, University of Colorado, Aurora, CO, USA. 14University of Michigan, Ann Arbor, MI, USA




RECURRENT PREGNANCY LOSS IN TYPE 3 VON WILLEBRAND DISEASE WITH A UNIQUE MUTATION PROFILE
Amanda D. Kaveney, Claire Philipp. Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA




VALUE OF FUNCTIONAL PROTEIN S ACTIVITY ASSAYS FOR DETECTION OF TYPE II PROTEIN S DEFICIENCY
Katharine A. Marsden, Shelbey Bauman, Peter F. Mannion, Morayma Reyes Gil. Cleveland Clinic Foundation, Cleveland, OH, USA




CLINICAL OUTCOMES IN MILD-MODERATE AND SEVERE PATIENTS WITH HEMOPHILIA B: RESULTS FROM A REAL-WORLD, MULTI-NATIONAL SURVEY
Sheena Thakkar1, Lisa Wilcox1, Valeria Merla1, Anna Kane1, Jose Alvir1, Surya Pemmaraju1, Jennifer Mellor2, Ella Morton2, Jade Garratt Wheeldon2, James Pike2, Nathan Ball2, Stevie Olsen2. 1Pfizer Inc, New York, NY, USA. 2Adelphi Real World, Bollington, United Kingdom




OUTCOMES IN NORTH AMERICAN PARTICIPANTS WHO RECEIVED EFANESOCTOCOG ALFA PROPHYLAXIS IN THE XTEND-1 STUDY
Annette von Drygalski1, Tung Wynn2, Doris Quon3, Anthony KC Chan4, Angela C Weyand5, Davide Matino6, Jennifer Dumont7, Andrew Wilson7, Umer Khan8, Sriya Gunawardena9. 1Division of Hematology/Oncology, Department of Medicine, University of California San Diego, San Diego, CA, USA. 2Department of Pediatrics, University of Florida, Gainesville, FL, USA. 3Luskin Orthopaedic Institute for Children, Los Angeles, CA, USA. 4Department of Pediatrics, McMaster Childrena, Hamilton, ON, Canada. 5Division of Hematology/Oncology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA. 6Division of Hematology a Thromboembolism, Department of Medicine, McMaster University, Hamilton, ON, Canada. 7Sanofi, Cambridge, MA, USA. 8Sanofi, San Diego, CA, USA. 9Sanofi, Bridgewater, NJ, USA




HEALTH-RELATED QUALITY OF LIFE AND TREATMENT BURDEN IN PATIENTS WITH HEMOPHILIA A/B WITHOUT INHIBITORS ON CONCIZUMAB PROPHYLAXIS: RESULTS FROM THE PHASE 3 EXPLORER8 STUDY
Guy Young1, Gary Benson2, Hermann Eichler3, Johnny Mahlangu4, Jesper Skov Neergaard5, Jan Odgaard-Jensen5, Jay Jay Thaung Zaw5, Jameela Sathar6, Huyen Tran7, Tadashi Matsushita8, Emily K. Waters9. 1Hemostasis and Thrombosis Center, Childrena, Los Angeles, CA, USA. 2Department of Hematology, Belfast Health and Social Care Trust, Belfast, Ireland. 3Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and University Hospital, Homburg, Saar, Germany. 4Department of Molecular Medicine and Haematology, School of Pathology, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg, South Africa. 5Novo Nordisk A/S, SAcborg, Denmark. 6Department of Haematology, Ampang Hospital, Selangor, Malaysia. 7Ronald Sawers Haemophilia Treatment Centre, Monash University, Melbourne, Australia. 8Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan. 9Novo Nordisk Inc, Plainsboro, NJ, USA


A8. ANTITHROMBOTIC THERAPY




ANTICOAGULANT MANAGEMENT OF CANCER-ASSOCIATED THROMBOSIS AND THROMBOCYTOPENIA: A RETROSPECTIVE CHART REVIEW
Umaima Abbas1, Ushra Khan1, Robin Mackenzie1, Rija Fatima2, Tzu-Fei Wang3, Caroline Hamm1, 4, 5, Andrea Cervi1, 4, 5. 1Schulich School of Medicine a Dentistry, University of Western Ontario, London, ON, Canada. 2Department of Translational Health Science, University of Windsor, Windsor, ON, Canada. 3Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON, Canada. 4Department of Biomedical Sciences, University of Windsor, Windsor, ON, Canada. 5Windsor Regional Hospital, Windsor, ON, Canada




A SURVEY OF CLINICIAN PRACTICE PATTERNS ON THE USE OF INFERIOR VENA CAVA FILTERS FOR VENOUS THROMBOEMBOLISM
Jillian Calandra1, Rahman Ladak2, Massimo Sementilli3, Alejandro Lazo-Langner2, 4, Deborah Siegal5, 6, Tzu-Fei Wang5, 6, Rong Luo7, Andrea Cervi7. 1WE-SPARK Health Institute, Windsor, ON, Canada. 2Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada. 3Department of Biomedical Sciences, University of Windsor, Windsor, ON, Canada. 4Lawson Health Research Institute, London, ON, Canada. 5Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. 6Ottawa Hospital Research Institute, Ottawa, ON, Canada. 7Windsor Regional Hospital, Windsor, ON, Canada




INR ABOVE FIVE WARFARIN EVENTS INPATIENT REQUIRE FOCUS ON PREVENTABLE CASES TO LOWER INCIDENCE
Benjamin/J Jung1, Lisa Baumann-Kreuziger1, 2, Garret Newkirk1. 1Froedtert and Medical College of Wisconsin, MIlwaukee, WI, USA. 2Versiti Blood Center of Wisconsin, Milwaukee, WI, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)




EVALUATION OF NURSE-MANAGED HEPARIN NOMOGRAM ADHERENCE AFTER IMPLEMENTATION OF AN ELECTRONIC MEDICAL RECORD-EMBEDDED HEPARIN CALCULATOR
Taylor Robichaux1, John Lindsley1, Vi Gilmore1, Rosemary Duncan1, Catherine Kiruthi1, Erica Willits2, Michael Streiff3, Rakhi Naik3, Jennifer Yui3, Kathryn Dane1. 1Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, USA. 2Department of Nursing, The Johns Hopkins Hospital, Baltimore, MD, USA. 3Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA




A COMPARISON OF TARGETED HIGH-RANGE VERSUS LOW-RANGE ANTI-XA GOAL FOR INTRAVENOUS UNFRACTIONATED HEPARIN IN PATIENTS WITH MECHANICAL CIRCULATORY SUPPORT DEVICES
Yue Wang, Long To, Mathew Jones, Kristin Griebe. Henry Ford Hospital, Detroit, MI, USA

5:15 - 6:45 PM
THROMBOSIS / HEMOSTASIS
ANTICOAGULATION FOR PATIENTS WITH BLEEDING RELATED CONDITIONS
Sheraton Ballroom I-II


5:15

ANTICOAGULANTS IN PATIENTS WITH BLEEDING DISORDERS
Bethany Samuelson Bannow.


5:45

DESCRIBING THE RISKS FOR BLEEDING AND THROMBOSIS UNIQUE TO PATIENTS WITH RENAL IMPAIRMENT
William Dager.


6:15

RESUMPTION OF ANTICOAGULATION POST BLEEDING EVENT
Dan Witt.

5:15 - 6:45 PM
BASIC SCIENCE
CUTTING TO THE CHASE- FIBRINOLYSIS
Sheraton Ballroom IV-V


5:15

ENGINEERING DEVICES TO MEASURE AND/OR ENHANCE FIBRINOLYSIS
Dante Disharoon.


5:45

TFPI AS A MODIFIER OF FIBRINOLYSIS AND BLEEDING IN FXI DEFICIENCY
Stephanie Rietsma.


6:15

INTERSECTION OF FIBRIN(OLYSIS) AND INFLAMMATION AT THE ORAL MUCOSA BARRIER
Lakmali Silva.

5:15 - 6:45 PM
LABORATORY
DISSOLVING THE CLOT OF THROMBILIA TESTING: CURRENT DIAGNOSTIC UPDATES AND CHALLENGES
Chicago Ballroom VII


5:15

UPDATES ON PROTEIN C AND PROTEIN S DEFICIENCY TESTING (HIGHLIGHTS AND CRITIQUES OF RECENT ISTH DOCUMENTS)
Marian Rollins-Raval.


5:45

CHALLENGES IN PRACTICAL APPLICATION OF LA TESTING GUIDELINES IN NORTH AMERICA: MIXING STUDIES AND BEYOND!
Jacqueline Poston, Andrew Goodwin.


6:15

PITFALLS AND CONSIDERATIONS FOR THROMBOPHILIA TESTING--HOW CAN LABORATORIES SUPPORT PATIENTS? (PURPURA FULMINANS, ACUTE DIC, APAS, INTERFERENCES ETC. )
Donna Castellone.

7:00 - 8:00 PM
SATELLITE SYMPOSIUM
ASK THE EXPERTS: TRANSFORMING CARE WITH GENE THERAPY FOR HEMOPHILIA LIVED EXPERIENCE PERSPECTIVES FROM PATIENTS AND PROVIDERS (SPONSORED BY BIOMARIN)
Chicago Ballroom IX-X

Join us for dinner and hear from a panel of health care providers with hemophilia gene therapy experience (clinical trial and post-FDA approval), as well as patients with years of post-treatment experience. Panelists will review clinical trial data and discuss patient treatment outcomes and expectations. Have your questions answered by the panel and learn how gene therapy can be implemented in your Hemophilia Treatment Center.



ELEVATING HEMOPHILIA CARE BEYOND BLEED MANAGEMENT: A MULTIDISCIPLINARY PANEL DIALOGUE TO BRIDGE GAPS IN PATIENT CARE (SPONSORED BY SANOFI)
Chicago Ballroom VI

Please join us for our panel of healthcare providers and patients/caregivers for a discussion on current unmet needs in hemophilia centered around findings from a Hemophilia Life Stages and Changes Global Survey of >2, 700 patients, caregivers, and hematologists. As treatment options evolve, so must expectations and goals on management of hemophilia. This symposium will explore how communication gaps between HCPs and patients can improve to achieve positive change and better quality of life.